Experience of Surgical Management of Gastrointestinal Stromal Tumors at a Tertiary Hospital of Nepal
Journal of Surgery
Volume 7, Issue 4, August 2019, Pages: 104-109
Received: Jun. 2, 2019; Accepted: Jul. 1, 2019; Published: Jul. 12, 2019
Views 91      Downloads 23
Authors
Dhruba Narayan Sah, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Ramesh Singh Bhandari, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Paleswan Joshi Lakhey, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Yogendra Prasad Singh, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Pradeep Vaidya, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Prasan Bir Singh Kansakar, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Bikal Ghimire, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Bishnu Prasad Kandel, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Jayant Kumar Sah, Surgical Gastroenterology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Article Tools
Follow on us
Abstract
Gastrointestinal stromal tumors (GISTs) are rare malignancies but a most common mesenchymal tumor. A multidisciplinary team approach is the optimal care of GIST patients after the remarkable outcomes with the development of molecular-targeted therapy. The objective is to determine the clinic-pathological spectrum and risk category of GIST along with perioperative outcomes. This is a retrospective review of GIST patients between September 2015 – August 2018 at Tribhuvan University Teaching Hospital (TUTH), Kathmandu, Nepal. Patients’ clinical data, histopathology, immunohistochemistry (IHC) and outcomes were recorded and analyzed. A total of 42 GIST patients were identified with age (19-81 years) and 69% were males. Stomach (35.7%) was the most common site followed by small bowel (23.8%) and duodenum (14.3%). Pain (40.5%) followed by bleeding (30.9%) were major indications. Max tumor dimensions were ranging from 2.8- 30 cm and median mitotic figures were 3 (0-35). Patients were stratified as high, intermediate, low and very low risk (36%, 32%, 32%, and 0% respectively). The majority were managed surgically out of which three cases underwent preoperative angioembolization. CD 117 was positive in 90.5%. Neoadjuvant imatinib given in 2 cases while adjuvant imatinib given in 18 cases. Over a median follow up of 18 months four patients expired while 32 had no issues. Surgical resection is the preferred choice of treatment with or without the molecular targeted drug therapy. Most tumors fall in the high-risk category.
Keywords
Gastrointestinal Stromal Tumor (GIST), TUTH, Imatinib
To cite this article
Dhruba Narayan Sah, Ramesh Singh Bhandari, Paleswan Joshi Lakhey, Yogendra Prasad Singh, Pradeep Vaidya, Prasan Bir Singh Kansakar, Bikal Ghimire, Bishnu Prasad Kandel, Jayant Kumar Sah, Experience of Surgical Management of Gastrointestinal Stromal Tumors at a Tertiary Hospital of Nepal, Journal of Surgery. Vol. 7, No. 4, 2019, pp. 104-109. doi: 10.11648/j.js.20190704.14
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
H Joensuu, C Fletcher, S Dimitrijevic, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002; 3 (11): 655-64.
[2]
BP Rubin, MC Heinrich, CL Corless. Gastrointestinal stromal tumour. Lancet. 2007; 369 (9574): 1731-41.
[3]
KM Kim, DW Kang, WS Moon, et al. Gastrointestinal stromal tumors in Koreans: it's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci. 2005; 20 (6): 977-84.
[4]
TM Parab, MJ DeRogatis, AM Boaz, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019; 10 (1): 144-54.
[5]
H Joensuu. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39 (10): 1411-9.
[6]
EESNWGJAooojotESfM Oncology. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2014; 25: iii21.
[7]
DH Koo, MH Ryu, KM Kim, et al. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Res Treat. 2016; 48 (4): 1155-66.
[8]
RP Dematteo, JS Gold, L Saran, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112 (3): 608-15.
[9]
HJ Koo, JH Shin, S Shin, et al. Efficacy and Clinical Outcomes of Transcatheter Arterial Embolization for Gastrointestinal Bleeding from Gastrointestinal Stromal Tumor. J Vasc Interv Radiol. 2015; 26 (9): 1297-304 e1.
[10]
K Akahoshi, M Oya, T Koga, Y Shiratsuchi. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018; 24 (26): 2806-17.
[11]
MA Beltran, KSJIJoS Cruces. Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study. 2007; 5 (3): 183-91.
[12]
A Aghdassi, A Christoph, F Dombrowski, et al. Gastrointestinal stromal tumors: clinical symptoms, location, metastasis formation, and associated malignancies in a single center retrospective study. 2018; 36 (5): 337-45.
[13]
M Miettinen, J Lasota. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130 (10): 1466-78.
[14]
H Joensuu, P Hohenberger, CL Corless. Gastrointestinal stromal tumour. Lancet. 2013; 382 (9896): 973-83.
[15]
JM Sanchez-Hidalgo, M Duran-Martinez, R Molero-Payan, et al. Gastrointestinal stromal tumors: A multidisciplinary challenge. World J Gastroenterol. 2018; 24 (18): 1925-41.
[16]
J Gong, W Kang, J Zhu, J Xu. CT and MR imaging of gastrointestinal stromal tumor of stomach: a pictorial review. Quant Imaging Med Surg. 2012; 2 (4): 274-9.
[17]
CD Fletcher, JJ Berman, C Corless, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. 2002; 10 (2): 81-9.
[18]
B Liegl, JL Hornick, CL Corless, CDJTAjosp Fletcher. Monoclonal antibody DOG1. 1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. 2009; 33 (3): 437-46.
[19]
AE Bannon, LR Klug, CL Corless, MCJEromd Heinrich. Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. 2017; 17 (5): 445-57.
[20]
P Rutkowski, E Bylina, A Wozniak, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour–the impact of tumour rupture on patient outcomes. 2011; 37 (10): 890-6.
[21]
JY Blay, S Bonvalot, P Casali, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16 (4): 566-78.
[22]
MD McCarter, CR Antonescu, KV Ballman, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012; 215 (1): 53-9; discussion 9-60.
[23]
M von Mehren, RL Randall, RS Benjamin, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14 (6): 758-86.
[24]
D Wang, Q Zhang, CD Blanke, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012; 19 (4): 1074-80.
[25]
H Joensuu, M Eriksson, K Sundby Hall, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2016; 34 (3): 244-50.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186